Fig. 1: IDentif.AI-x workflow and its alignment with the pandemic response therapies prioritization. | npj Digital Medicine

Fig. 1: IDentif.AI-x workflow and its alignment with the pandemic response therapies prioritization.

From: The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens

Fig. 1

IDentif.AI-x systematically ranks drug combinations for further preclinical and potentially clinical deployment from a multitude of potential therapies. Clinical applicability considerations are integrated into IDentif.AI-x workflow to pre-emptively best position the optimized combinations for a clinical translation. EIDD-1931 (metabolite of EIDD-2801 (molnupiravir)), baricitinib (BRT), ebselen (EBS), selinexor (SEL), masitinib (MST), nafamostat mesylate (NFM), telaprevir (VX-950; TPV), SN-38 (metabolite of irinotecan), imatinib mesylate (IMT), remdesivir (RDV), lopinavir (LPV), and ritonavir (RTV) were included in the original pool in this study. CPE cytopathic effects. D-R dose-response. OACD orthogonal array composite design.

Back to article page